| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Serine/threonine-protein kinase Chk1, CHK1 checkpoint homolog, Cell cycle checkpoint kinase, Checkpoint kinase-1, CHEK1, CHK1 |
| Entrez GeneID | 1111 |
| WB Predicted band size | 54.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This CHK1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 425-455 amino acids from the C-terminal region of human CHK1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于CHK1抗体的3篇参考文献示例(注：文献标题和作者为示例性内容，具体文献需根据实际数据库检索确认)：
---
1. **文献名称**：*CHK1 in the DNA Damage Response: A Key Therapeutic Target*
**作者**：Zhou, B.B. et al.
**摘要**：本文探讨了CHK1在DNA损伤应答中的核心作用，利用特异性CHK1抗体检测其磷酸化状态及活性变化，揭示了CHK1抑制剂在增强化疗敏感性中的潜力。
2. **文献名称**：*Immunoblotting Analysis of CHK1 Activation in Cancer Cell Lines*
**作者**：Tse, A.N. et al.
**摘要**：研究通过CHK1抗体进行Western blot分析，证明多种癌细胞中CHK1的组成性激活，并验证其作为预测放疗/化疗响应的生物标志物的可行性。
3. **文献名称**：*Targeting CHK1 for Potentiating ATR Inhibitor Efficacy in Pancreatic Cancer*
**作者**：Matheson, C.J. et al.
**摘要**：使用CHK1抗体评估胰腺癌模型中CHK1蛋白水平，发现抑制CHK1可增强ATR抑制剂的抗肿瘤效果，为联合治疗提供理论支持。
---
**备注**：以上文献信息为示例，实际引用时请通过PubMed、Web of Science等平台检索具体文献，并核对作者、标题及摘要的准确性。
**Background of CHK1 Antibody**
CHK1 (Checkpoint kinase 1) is a serine/threonine kinase critical for maintaining genomic stability during cell cycle progression. It plays a central role in the DNA damage response (DDR) by regulating cell cycle checkpoints, particularly the S and G2/M phases. Activated primarily by ATR (ataxia-telangiectasia and Rad3-related kinase) in response to replication stress or DNA damage, CHK1 phosphorylates downstream targets like CDC25 phosphatases, halting cell cycle progression to allow DNA repair. Dysregulation of CHK1 is linked to genomic instability and cancer progression.
CHK1 antibodies are essential tools in research for detecting and quantifying CHK1 expression, phosphorylation status, and subcellular localization. These antibodies are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to study DDR mechanisms, replication stress responses, and cell cycle regulation. In cancer biology, CHK1 antibodies help evaluate CHK1’s role as a therapeutic target, given its involvement in protecting cancer cells from replication stress induced by chemotherapy or radiation.
Additionally, CHK1 inhibitors are being explored in clinical trials, and CHK1 antibodies aid in assessing inhibitor efficacy or resistance mechanisms. Validated CHK1 antibodies are crucial for distinguishing between total CHK1 and its activated (phosphorylated) forms, providing insights into DDR pathway dynamics. Their specificity and reliability are critical for advancing studies on cancer therapy, synthetic lethality, and the development of biomarkers for treatment response.
×
